Equities research analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to announce $3.19 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Blueprint Medicines’ earnings. The lowest sales estimate is $1.13 million and the highest is $5.94 million. Blueprint Medicines reported sales of $5.89 million during the same quarter last year, which suggests a negative year-over-year growth rate of 45.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 1st.
On average, analysts expect that Blueprint Medicines will report full-year sales of $7.20 million for the current financial year, with estimates ranging from $4.33 million to $8.77 million. For the next year, analysts expect that the firm will post sales of $8.51 million per share, with estimates ranging from $1.02 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.23). Blueprint Medicines had a negative net margin of 1,068.27% and a negative return on equity of 37.00%. The business had revenue of $0.95 million during the quarter, compared to analyst estimates of $2.82 million. During the same quarter last year, the business earned ($0.84) earnings per share. Blueprint Medicines’s revenue for the quarter was down 83.7% on a year-over-year basis.
Several research firms recently weighed in on BPMC. JMP Securities set a $109.00 target price on shares of Blueprint Medicines and gave the company a “buy” rating in a research note on Monday, April 16th. Wedbush raised their target price on shares of Blueprint Medicines from $98.00 to $106.00 and gave the company an “outperform” rating in a research note on Monday, April 16th. BidaskClub cut shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $87.20.
Shares of Blueprint Medicines traded down $2.79, hitting $67.00, during midday trading on Tuesday, Marketbeat Ratings reports. The stock had a trading volume of 16,787 shares, compared to its average volume of 593,964. Blueprint Medicines has a 12 month low of $41.41 and a 12 month high of $109.00. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.05 billion, a PE ratio of -17.80 and a beta of 1.02.
In other news, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $78.90, for a total value of $1,578,000.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at $1,578,000. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.15% of the company’s stock.
Several institutional investors have recently made changes to their positions in BPMC. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Blueprint Medicines by 57.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 680 shares in the last quarter. Amalgamated Bank raised its stake in Blueprint Medicines by 16.9% in the fourth quarter. Amalgamated Bank now owns 5,777 shares of the biotechnology company’s stock valued at $436,000 after purchasing an additional 837 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Blueprint Medicines by 1.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 109,788 shares of the biotechnology company’s stock valued at $8,279,000 after purchasing an additional 1,125 shares in the last quarter. Xact Kapitalforvaltning AB raised its stake in Blueprint Medicines by 39.0% in the first quarter. Xact Kapitalforvaltning AB now owns 5,351 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in Blueprint Medicines by 48.2% in the first quarter. Great West Life Assurance Co. Can now owns 4,937 shares of the biotechnology company’s stock valued at $453,000 after purchasing an additional 1,605 shares in the last quarter. 97.62% of the stock is owned by institutional investors.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.